Related Experiment Video

Updated: Sep 7, 2026

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

Dose-dependent subcutaneous absorption of porcine, bovine and human NPH insulins

P Hildebrandt, K Birch, L Sestoft

    Acta Medica Scandinavica
    |January 1, 1984
    PubMed

    More Related Videos

    Lipopolysaccharide Infusion as a Porcine Endotoxemic Shock Model05:52

    Lipopolysaccharide Infusion as a Porcine Endotoxemic Shock Model

    Published on: December 8, 2023

    A Standardized Ex Vivo Porcine Oromucosal Model for Evaluating Peptide Fluxes09:17

    A Standardized Ex Vivo Porcine Oromucosal Model for Evaluating Peptide Fluxes

    Published on: June 9, 2026

    Related Concept Videos

    Routes of Drug Administration: Parenteral01:25

    Routes of Drug Administration: Parenteral

    The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
    The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
    The IV route is often...
    Bioavailability: Overview01:13

    Bioavailability: Overview

    Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
    Insulin: Biosynthesis, Chemistry, and Preparation01:25

    Insulin: Biosynthesis, Chemistry, and Preparation

    The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
    Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
    Insulin Formulations: Types and Delivery01:27

    Insulin Formulations: Types and Delivery

    Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
    Short-acting insulins are divided into rapid-acting...
    Insulin: Dosing Regimen and Adverse Effects01:16

    Insulin: Dosing Regimen and Adverse Effects

    Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
    The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
    Oral Hypoglycemic Agents: Glinides01:06

    Oral Hypoglycemic Agents: Glinides

    Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...